Biomarkers useful in the treatment of IL-23A related diseases
This invention generally relates to biomarkers useful in the treatment of IL-23 related diseases, in particular inflammatory diseases such as psoriasis. The invention also relates to methods of using the biomarkers disclosed herein, for example in therapies utilizing IL-23 antagonists.
1. A method for detecting the presence or absence of a response in a patient after administration of an anti-IL-23A antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO: 18 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 19, comprising:
a) obtaining a biological sample from the patient;
b) measuring in said sample the level of one or more biomarkers, or the level of expression of one or more biomarkers;
c) comparing the level to control value of the level of the one or more biomarkers; and
d) determining whether or not the difference in levels between the sample and the control reflects a response in the patient,
wherein the one or more biomarkers comprises β-defensin 2.
2. The method of claim 1 , wherein the level of the gene or the protein of said one or more biomarkers is measured.
3. The method of claim 1 , wherein the patient suffers from psoriasis.
4. The method of claim 1 , wherein the control value is calculated using samples from subjects that do not suffer from psoriasis.
5. The method of claim 1 , wherein the control value is determined using samples from known psoriasis patients.
6. The method of claim 1 , wherein the control value is determined using at least one previous sample taken from the patient.
7. The method of claim 1 , wherein the biological sample is a skin biopsy, blood, plasma or serum sample.
8. The method claim 1 , wherein the levels of biomarkers are determined by RNA sequencing or ELISA.
9. The method of claim 1 , wherein the one or more biomarkers further comprises S-100A7 or neutrophil gelatinase lipocalin.
10. The method of claim 1 , wherein the one or more biomarkers further comprises S-100A7 and neutrophil gelatinase lipocalin.